Search research articles
Contact Us
Filters
Showing results (41-50 of 181) with videos related to
Page
of 19
Sort By:
Journal of Neurovirology
|
March 16, 2018
Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)
Arkaitz Imaz, Jordi Niubó, Alieu Amara, et al.
Pharmacogenetics and Genomics
|
May 20, 2016
HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience
Cristina Ruiz-Iruela, Núria Padullés-Zamora, Daniel Podzamczer-Palter, et al.
Journal of the International AIDS Society
|
November 14, 2014
Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
Elena Ferrer, Antonio Navarro, Jordi Curto, et al.
AIDS Research and Human Retroviruses
|
December 1, 2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
José R Santos, Josep M Llibre, Pere Domingo, et al.
Journal of the International AIDS Society
|
November 15, 2014
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
Silvana Di Yacovo, Jose Molto, Elena Ferrer, et al.
AIDS (London, England)
|
December 15, 2010
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
Mark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2018
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)
Arkaitz Imaz, Jordi Niubó, Mackenzie L Cottrell, et al.
AIDS Research and Human Retroviruses
|
June 9, 2009
How much fat loss is needed for lipoatrophy to become clinically evident?
Daniel Podzamczer, Elena Ferrer, Esteban Martínez, et al.
HIV Medicine
|
March 25, 2025
Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV
Maria Saumoy, Analuz Fernandez, Juan Tiraboschi, et al.
Journal of the International AIDS Society
|
November 14, 2014
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
José Ramón Santos, María Saumoy, Adrian Curran, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 181) with videos related to
Sort By:
Page
of 19
Journal of Neurovirology
|
March 16, 2018
Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)
Arkaitz Imaz, Jordi Niubó, Alieu Amara, et al.
Pharmacogenetics and Genomics
|
May 20, 2016
HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience
Cristina Ruiz-Iruela, Núria Padullés-Zamora, Daniel Podzamczer-Palter, et al.
Journal of the International AIDS Society
|
November 14, 2014
Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
Elena Ferrer, Antonio Navarro, Jordi Curto, et al.
AIDS Research and Human Retroviruses
|
December 1, 2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
José R Santos, Josep M Llibre, Pere Domingo, et al.
Journal of the International AIDS Society
|
November 15, 2014
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
Silvana Di Yacovo, Jose Molto, Elena Ferrer, et al.
AIDS (London, England)
|
December 15, 2010
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
Mark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2018
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)
Arkaitz Imaz, Jordi Niubó, Mackenzie L Cottrell, et al.
AIDS Research and Human Retroviruses
|
June 9, 2009
How much fat loss is needed for lipoatrophy to become clinically evident?
Daniel Podzamczer, Elena Ferrer, Esteban Martínez, et al.
HIV Medicine
|
March 25, 2025
Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV
Maria Saumoy, Analuz Fernandez, Juan Tiraboschi, et al.
Journal of the International AIDS Society
|
November 14, 2014
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
José Ramón Santos, María Saumoy, Adrian Curran, et al.
Page
of 19